Condition: Breast Cancer · Sponsor: Shengjing Hospital
To investigate the efficacy of albumin-bound paclitaxel combined with carboplatin versus epirubicin combined with docetaxel as neoadjuvant therapy for triple-negative breast cancer.
This description comes directly from the study's public registry record.
Xi Gu, M.D. · +86 18940255116 · jadegx@163.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital Affiliated to Harbin Medical University | Harbin, Heilongjiang, China | Recruiting |
| The Second Hospital of Jilin University | Changchun, Jilin, China | Recruiting |
| Dalian Municipal Central Hospital | Dalian, Liaoning, China | Recruiting |
| Panjin Liaohe Oilfield Gem Flower Hospital | Panjin, Liaoning, China | Recruiting |
| Shengjing Hospital of China Medical University | Shenyang, Liaoning, China | Recruiting |
| The Fourth Affiliated Hospital of China Medical University | Shenyang, Liaoning, China | Recruiting |
| Liaoning Cancer Hospital & Institute | Shenyang, Liaoning, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04136782